It is Poised to be a Bull Market for Editas Medicine Inc (EDIT)

With 1.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.85 million shares. The 52-week range on EDIT shows that it touched its highest point at $11.91 and its lowest point at $6.08 during that stretch. It currently has a 1-year price target of $15.07. Beta for the stock currently stands at 2.01.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EDIT was down-trending over the past week, with a drop of -2.54%, but this was down by -27.63% over a month. Three-month performance dropped to -29.66% while six-month performance rose 5.20%. The stock lost -1.75% in the past year, while it has lost -28.13% so far this year. A look at the trailing 12-month EPS for EDIT yields -2.06 with Next year EPS estimates of -2.73. For the next quarter, that number is -0.63. This implies an EPS growth rate of -27.84% for this year and -5.64% for next year. EPS is expected to grow by 1.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 2.88%.

Float and Shares Shorts:

At present, 81.77 million EDIT shares are outstanding with a float of 80.82 million shares on hand for trading. On Mar 15, 2024, short shares totaled 13.93 million, which was 17.02% higher than short shares on Feb 15, 2024. In addition to Dr. Gilmore O’Neill M.D. as the firm’s President, CEO & Director, Dr. Baisong Mei M.D., Ph.D. serves as its Senior VP & Chief Medical Officer.

Institutional Ownership:

Through their ownership of 75.61% of EDIT’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EDIT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, EDIT has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and EDIT currently yields $0.00. In the past year, EDIT’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, EDIT has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.